Last Updated: August 4, 2026

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Azelastine Hydrochloride And Fluticasone Propionate patents expire, and when can generic versions of Azelastine Hydrochloride And Fluticasone Propionate launch?

Azelastine Hydrochloride And Fluticasone Propionate is a drug marketed by Apotex, Padagis Israel, and Teva Pharms Usa Inc. and is included in three NDAs.

The generic ingredient in AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
  • What are the global sales for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
  • What is Average Wholesale Price for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE?
Summary for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
US Patents:0
Applicants:3
NDAs:3

US Patents and Regulatory Information for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 207712-001 Apr 28, 2017 AB RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Padagis Israel AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 208111-001 Feb 18, 2021 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Teva Pharms Usa Inc AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE azelastine hydrochloride; fluticasone propionate SPRAY, METERED;NASAL 208436-001 Apr 8, 2025 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.